MiMedx Group, Inc. (NASDAQ:MDXG) Shares Purchased by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership raised its holdings in shares of MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) by 484.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 362,481 shares of the company's stock after buying an additional 300,433 shares during the period. Arrowstreet Capital Limited Partnership owned about 0.25% of MiMedx Group worth $3,487,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Norges Bank bought a new position in MiMedx Group in the 4th quarter worth $4,020,000. JPMorgan Chase & Co. increased its stake in MiMedx Group by 133.1% during the fourth quarter. JPMorgan Chase & Co. now owns 693,106 shares of the company's stock worth $6,668,000 after acquiring an additional 395,739 shares during the last quarter. EntryPoint Capital LLC purchased a new stake in MiMedx Group during the 4th quarter valued at $472,000. LPL Financial LLC boosted its stake in shares of MiMedx Group by 213.8% during the 4th quarter. LPL Financial LLC now owns 143,845 shares of the company's stock worth $1,384,000 after purchasing an additional 98,004 shares during the period. Finally, KLP Kapitalforvaltning AS purchased a new position in shares of MiMedx Group during the fourth quarter valued at approximately $202,000. 79.15% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently commented on MDXG shares. StockNews.com raised shares of MiMedx Group from a "buy" rating to a "strong-buy" rating in a research note on Friday, April 4th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $13.00 target price on shares of MiMedx Group in a report on Thursday, February 27th.

Remove Ads

Insider Activity at MiMedx Group

In other news, CAO William Frank Iv Hulse sold 81,446 shares of the stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $7.80, for a total value of $635,278.80. Following the transaction, the chief accounting officer now owns 494,774 shares in the company, valued at approximately $3,859,237.20. This represents a 14.13 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Kimberly Maersk-Moller sold 4,106 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total transaction of $32,396.34. Following the sale, the insider now owns 310,836 shares of the company's stock, valued at $2,452,496.04. This represents a 1.30 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 144,018 shares of company stock worth $1,130,312. Company insiders own 1.30% of the company's stock.

MiMedx Group Price Performance

Shares of MiMedx Group stock traded down $0.08 on Monday, reaching $6.76. The company's stock had a trading volume of 14,160 shares, compared to its average volume of 581,270. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10. The stock has a 50-day moving average price of $7.86 and a 200-day moving average price of $8.00. The company has a market capitalization of $996.19 million, a P/E ratio of 12.25 and a beta of 1.74. MiMedx Group, Inc. has a 52-week low of $5.47 and a 52-week high of $10.14.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share for the quarter, hitting analysts' consensus estimates of $0.07. The firm had revenue of $92.91 million for the quarter, compared to analyst estimates of $89.42 million. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. Analysts expect that MiMedx Group, Inc. will post 0.3 EPS for the current year.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.